Does Dr. MEHMET AKCE have financial conflicts of interest?

Dr. MEHMET AKCE (M.D) has received a total of $39,002 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $39,002 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MEHMET AKCE?

According to CMS Open Payments data, Dr. MEHMET AKCE received funding from ASTRAZENECA PHARMACEUTICALS ($9,511), ASTRAZENECA UK LIMITED ($8,220), and GLAXOSMITHKLINE ($4,400).

Does Dr. MEHMET AKCE receive research grants or speaking fees?

Dr. MEHMET AKCE has received $39,002 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MEHMET AKCE

M.DReal-Time Hydrated

Specialty: Internal Medicine, Hematology & Oncology

Practice Location: BIRMINGHAM, AL 35233

NPI Number: 1639480106

LIFETIME INDUSTRY VALUE

$39,002

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. AKCE is a verified Internal Medicine, Hematology & Oncology practitioner based in BIRMINGHAM, AL.

Between 2021 and 2024, Dr. AKCE had an overall industry promotional and research financial footprint of $39,002 as recorded in the federal CMS Open Payments database.

$39,002 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. AKCE's primary funding source is ASTRAZENECA PHARMACEUTICALS, which accounts for $9,511 (representing 24.4% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ASTRAZENECA PHARMACEUTICALS

Rank 1

$9,511

24.4%

ASTRAZENECA UK LIMITED

Rank 2

$8,220

21.1%

GLAXOSMITHKLINE

Rank 3

$4,400

11.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.